NEW YORK, May 23 (GenomeWeb News) - Proteome Sciences today said it has penned a license agreement with bioMerieux to use its biomarkers in blood to detect, diagnose, and monitor stroke.
Under the terms of the agreement, bioMerieux will test Proteome Sciences' biomarkers for a stroke diagnostic panel across a patient population in Continental Europe.
The biomarkers were discovered and validated using a combination of different proteomic approaches, all of which are available for external use through the proprietary ProteoSHOP platform.
Financial terms were not disclosed.